Skip to content

Study · Randomized controlled trial · n = 500 · 2025

7 results

Abaloparatide effects on BMD in acetabular regions corresponding to DeLee and Charnley zones in women with postmenopausal osteoporosis.

Sheth NP, Krohn K, Torkelson J, Winzenrieth R, Humbert L, Pearman L, Wang Y, Boxberger JI, Bostrom MP

Bone reports19 Jul 2025

PMID40786602 (opens in a new tab)PMCIDPMC12332864 (opens in a new tab)DOI10.1016/j.bonr.2025.101858 (opens in a new tab)PepBankPUB-40786602
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

BackgroundAcetabular bone loss in patients with osteoporosis is associated with increased risk of acetabular fragility fractures, significant morbidity, and can increase risk of complications in patients undergoing total hip arthroplasty. The anabolic osteoporosis treatment abaloparatide increases total hip areal bone mineral density (BMD), but its effect on acetabular BMD is unknown.MethodsAnatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group) from the phase 3 ACTIVE trial to virtually place a hemispherical shell model of an acetabular cup and define regions of interest corresponding to DeLee and Charnley zones 1 (R1), 2 (R2), and 3 (R3). Changes in BMD from baseline at 6 and 18 months were calculated. Statistical significance was tested using a mixed model with repeated measures. Local mean changes in BMD were depicted by alignment of DXA scans via intensity-based registration onto a reference scan.ResultsAbaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo. Mean BMD increases with abaloparatide were 8.38 % (R1), 7.25 % (R2), and 9.73 % (R3) at 18 months. BMD increases were homogenously distributed throughout the regions. With placebo, localized losses in BMD were noted after 18 months.ConclusionsAbaloparatide treatment rapidly and progressively increases BMD in acetabular zones in PMO.Clinical trial numberNCT01343004.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with postmenopausal osteoporosis, abaloparatide increased acetabular BMD in DeLee and Charnley zone R1 versus placebo at 6 months.

    In plain wordsIn women with osteoporosis, abaloparatide increased acetabular bone density in R1 more than placebo at 6 months.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAcetabular BMD in R1 at 6 months
    Study

    n = 500

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Abaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo.
    1 context sentence
    Summary · context
    Anatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group)
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with postmenopausal osteoporosis, abaloparatide increased acetabular BMD in DeLee and Charnley zone R2 versus placebo at 6 months.

    In plain wordsIn women with osteoporosis, abaloparatide increased acetabular bone density in R2 more than placebo at 6 months.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAcetabular BMD in R2 at 6 months
    Study

    n = 500

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Abaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo.
    1 context sentence
    Summary · context
    Anatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group)
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with postmenopausal osteoporosis, abaloparatide increased acetabular BMD in DeLee and Charnley zone R3 versus placebo at 6 months.

    In plain wordsIn women with osteoporosis, abaloparatide increased acetabular bone density in R3 more than placebo at 6 months.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAcetabular BMD in R3 at 6 months
    Study

    n = 500

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Abaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo.
    1 context sentence
    Summary · context
    Anatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group)
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with postmenopausal osteoporosis, abaloparatide increased R1 BMD by 8.38% at 18 months, with a significant increase versus placebo.

    In plain wordsIn women with osteoporosis, abaloparatide increased R1 bone density more than placebo at 18 months.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAcetabular BMD in R1 at 18 months
    Study

    n = 500

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/d · 18 monthsAs given in this study (human).

    Measurements

    BMD change
    8.38%
    abaloparatide R1 at 18 months versus baseline

    Source sentences

    Summary
    Mean BMD increases with abaloparatide were 8.38 % (R1), 7.25 % (R2), and 9.73 % (R3) at 18 months.
    2 context sentences
    Summary · context
    Abaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo.
    Summary · context
    Anatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group)
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with postmenopausal osteoporosis, abaloparatide increased R2 BMD by 7.25% at 18 months, with a significant increase versus placebo.

    In plain wordsIn women with osteoporosis, abaloparatide increased R2 bone density more than placebo at 18 months.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAcetabular BMD in R2 at 18 months
    Study

    n = 500

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/d · 18 monthsAs given in this study (human).

    Measurements

    BMD change
    7.25%
    abaloparatide R2 at 18 months versus baseline

    Source sentences

    Summary
    Mean BMD increases with abaloparatide were 8.38 % (R1), 7.25 % (R2), and 9.73 % (R3) at 18 months.
    2 context sentences
    Summary · context
    Abaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo.
    Summary · context
    Anatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group)
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with postmenopausal osteoporosis, abaloparatide increased R3 BMD by 9.73% at 18 months, with a significant increase versus placebo.

    In plain wordsIn women with osteoporosis, abaloparatide increased R3 bone density more than placebo at 18 months.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAcetabular BMD in R3 at 18 months
    Study

    n = 500

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/d · 18 monthsAs given in this study (human).

    Measurements

    BMD change
    9.73%
    abaloparatide R3 at 18 months versus baseline

    Source sentences

    Summary
    Mean BMD increases with abaloparatide were 8.38 % (R1), 7.25 % (R2), and 9.73 % (R3) at 18 months.
    2 context sentences
    Summary · context
    Abaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo.
    Summary · context
    Anatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group)
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with postmenopausal osteoporosis, abaloparatide-associated BMD increases were homogeneous throughout the acetabular regions.

    In plain wordsIn women with osteoporosis, bone density increases with abaloparatide were evenly distributed throughout the acetabular regions.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableSpatial distribution of BMD increases
    Study

    n = 250

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/dAs given in this study (human).

    Source sentences

    Summary
    BMD increases were homogenously distributed throughout the regions.
    2 context sentences
    Summary · context
    Abaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo.
    Summary · context
    Anatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01343004

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

Radius Health, Inc.n = 2,463Apr 2011 to Oct 2014

Osteoporosis · Postmenopausal Osteoporosis

Trial pageClinicalTrials.govUpdated 1 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.